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ABSTRACT
Objectives The UK government is proposing to cease 
cutting the local authority public health grant by 
reallocating part of the treatment budget to preventative 
activity. This study examines whether this proposal 
is evidenced based and, in particular, whether these 
resources are best reallocated to prevention, or whether 
this expenditure would generate more health gains if used 
for treatment.
Methods Instrumental variable regression methods 
are applied to English local authority data on mortality, 
healthcare and public health expenditure to estimate the 
responsiveness of mortality to variations in healthcare 
and public health expenditure in 2013/14. Using a well- 
established method, these mortality results are converted 
to a quality- adjusted life year (QALY) basis, and this 
facilitates the estimation of the cost per QALY for both 
National Health Service (NHS) healthcare and local public 
health expenditure.
Results Saving lives and improving the quality of life 
requires resources. Our estimates suggest that each 
additional QALY costs about £3800 from the local public 
health budget, and that each additional QALY from the NHS 
budget costs about £13 500. These estimates can be used 
to calculate the number of QALYs generated by a budget 
boost. If we err on the side of caution and use the most 
conservative estimates that we have, then an additional £1 
billion spent on public health will generate 206 398 QALYs 
(95% CI 36 591 to 3 76 205 QALYs), and an additional £1 
billion spent on healthcare will generate 67 060 QALYs 
(95% CI 21 487 to 112 633 QALYs).
Conclusions Additional public health expenditure is very 
productive of health and is more productive than additional 
NHS expenditure. However, both types of expenditure are 
more productive of health than the norms used by National 
Institute for Health and Care Excellence (£20 000–£30 000 
per QALY) to judge whether new therapeutic technologies 
are suitable for adoption by the NHS.
INTRODUCTION
The UK’s National Health Service (NHS) 
spends about 5% of its annual budget 
on preventative activity with most of the 
remainder on treatment.1 However, most 
observers agree that prevention is better than 
cure and two recent government publications 
emphasise the importance of prevention if the 
government’s target gains in life expectancy 
by 2035 are to be realised.2–4 The govern-
ment’s 2019 Spending Review announced 
that cuts to the public health grant will 
cease and that a real- terms increase from 
2019/2020 to 2020/2021 will be achieved 
by a reprioritisation within the Department 
of Health’s budget.5 6 Although there is 
some debate about whether the increased 
funding will even compensate for increased 
costs,7 this reprioritisation raises the issue of 
whether these resources are best reallocated 
to prevention, or whether this expenditure 
would generate more health gains if used for 
treatment.
There is considerable evidence that specific 
individual preventative interventions generate 
substantial health benefits. For example, a 
study of the cost per quality- adjusted life year 
(QALY) associated with public health inter-
ventions assessed by the National Institute for 
Health and Care Excellence (NICE) over two 
5- year periods reported that the median cost 
per QALY was £1053 between 2005 and 2010, 
and £7843 between 2011 and 2016.8 Both of 
these cost per QALY figures are far below 
the £30 000 threshold that NICE uses for 
the approval of new therapeutic treatments 
within the NHS.9
Strengths and limitations of this study
 Ź Cross- sectional analysis of the impact of public 
health and healthcare expenditure on mortality.
 Ź The endogenous nature of expenditure is accommo-
dated via the use of instrumental variable methods.
 Ź The analysis includes controls for the need for 
healthcare expenditure.
 Ź The estimated mortality effects are converted into 
quality- adjusted life year effects.
 Ź There may be other healthcare need factors beyond 
those included in this study.
 on N
ovem
ber 2, 2020 by guest. P
rotected by copyright.
http://bm
jopen.bm
j.com
/
B
M
J O
pen: first published as 10.1136/bm
jopen-2019-036411 on 10 O
ctober 2020. D
ow
nloaded from
 
2 Martin S, et al. BMJ Open 2020;10:e036411. doi:10.1136/bmjopen-2019-036411
Open access 
Studies of individual public health interventions are 
useful but, if budgets are reallocated, we need to know 
the health gains associated with the increased spending 
on public health across all types of investments and the 
health losses associated with reduced spending on treat-
ment (again, across all programmes that are likely to be 
curtailed). In other words, we need to know the health 
effects at the margin of changes in the totality of the 
public health and healthcare budgets.
There is some American evidence on the effect of public 
health expenditure on mortality but the relevance of this 
for the UK is limited because the US healthcare system 
is very different and these studies do not simultaneously 
account for the impact of treatment expenditure.10 There 
is considerable evidence about the marginal productivity 
of English NHS healthcare (treatment) expenditure.11 12 
However, we want to investigate the marginal produc-
tivity of preventative expenditure while simultaneously 
controlling for treatment expenditure, and the inclusion 
of prevention expenditure in the health outcome specifi-
cation may affect the estimated marginal productivity of 
treatment expenditure.
Here, we exploit the availability of a funding formula 
for the public health grant. This determines how much 
of the total national budget is allocated to each local 
authority (LA). Some components of this formula are 
conditionally exogenous, that is, they are not related 
to health outcomes after controlling for the need for 
healthcare, except through their influence on the level 
of expenditure, and this makes it possible to identify the 
causal effect of changes in expenditure on mortality.
At the time of this study, the most recent mortality 
data available at a local level was for 2013/2014/2015 
combined, and hence we relate expenditure in 2013/2014 
to a measure of mortality for these 3 years. Moreover, 
by converting healthcare (treatment) expenditure as 
reported by Clinical Commissioning Groups (CCGs) to 
an LA geography, we are also able to estimate a health 
outcome specification that includes both treatment 
(healthcare) and prevention (public health) expendi-
ture. This enables us to identify the relative contribution 
of both types of expenditure to reductions in mortality.
METHODS
Institutional context
The English NHS is a largely centrally planned and 
publicly funded healthcare system. Its income comes 
almost entirely from national taxation. Access to the 
Service is usually achieved via general practitioners who 
act as gatekeepers to secondary care and pharmaceuti-
cals. With some minor exceptions, the service is free at 
the point of consumption for patients.
The service is organised geographically, with responsi-
bility for the local management of the NHS delegated to 
local health authorities. For our study year (2013/2014), 
each authority (CCG) was assigned a fixed annual budget 
by the national ministry (the Department of Health) 
within which they were supposed to meet expenditure 
on most types of healthcare including inpatient care, 
outpatient and community care, and pharmaceutical 
prescriptions.
We use their reported expenditure from the programme 
budgeting dataset as a measure of local healthcare expen-
diture.13 Primary care, specialised commissioning and 
national public health programmes were administered 
centrally. £2203 m was made available for these nationally 
funded public health programmes including those for 
immunisation (eg, for hepatitis B, for tuberculosis and for 
measles, mumps and rubella (MMR)) and for screening 
(eg, for exposure to HIV and for cervical cancer).14
Responsibility for local public health was delegated to 
local government with each ‘unitary’ or upper tier LA 
receiving a fixed annual budget, ring- fenced for public 
health activities. Here, our focus is on the impact of the 
local public health grant because we do not have data 
for expenditure on national programmes by local area. 
In 2013/2014, LAs spent over £2500 m on public health 
services including £630 m on sexual health services (eg, 
for sexually transmitted infection (STI) testing and 
treatment, and for contraception), £800 m on substance 
(drugs and alcohol) misuse services, £150 m on stop 
smoking and tobacco control services, and £240 m on 
health programmes for children aged 5–19.15
We sometimes refer to public health expenditure as 
‘preventative’ and CCG healthcare expenditure as ‘treat-
ment’ (for ill health). This is more out of a desire to avoid 
repetition rather than any belief that all expenditure 
funded by the public health grant is preventative and/
or that all healthcare expenditure is solely for treatment. 
For example, some expenditure from the public health 
grant could be considered as treatment (eg, expenditure 
on substance misuse treatment services) and some expen-
diture by CCGs will be preventative (eg, on medication 
for blood pressure and blood cholesterol). This issue is 
discussed further in the online supplemental appendix 
A1 . Strictly speaking, we are comparing the productivity 
of the public health grant with CCG healthcare expendi-
ture but we believe that it is reasonable to think of this as 
a comparison of the marginal productivity of preventative 
and treatment expenditure.
Estimation strategy
Studies estimating the relationship between any form of 
health expenditure and mortality typically estimate an 
outcome equation of the form:
 
ln(mortality rate) = f[ln(health expenditure per person)]
+controls for need + e  
(1)
where expenditure is likely to be endogenous, the 
controls reflect the need for health expenditure, and e 
reflects everything not included elsewhere in the speci-
fication.16 17 We want to estimate this specification, first 
with public health as the sole expenditure variable, and 
then with both public health and healthcare expenditure 
as two separate variables.
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Even after controlling for observable need for health 
expenditure, estimating the impact of health expendi-
ture on mortality is challenging for two reasons and these 
are illustrated in the top half of figure 1: first, there might 
be some reverse causation with historical mortality influ-
encing the current level of expenditure; and second, 
there might be some unobserved factor that is driving 
both expenditure and mortality. Our estimation approach 
involves finding variables (known as ‘instruments’) that 
are good predictors of expenditure but which have no 
direct impact on either mortality or unobserved factors.
These instruments are used to predict the level of 
expenditure that is not influenced by either historical 
mortality or unobserved factors. Having severed the link 
with unobserved factors and mortality, the predicted level 
of expenditure can then be used in a regression model to 
examine the causal impact of expenditure on mortality 
(bottom half of figure 1).
We use the resource allocation formula for the public 
health grant to LAs as a source of instruments for public 
health expenditure. This formula has three components—
for mandatory services, for non- mandatory services, and 
for substance misuse services—and each component has 
its own formula. Although the precise formula differs for 
each component, overall, the public health budget per 
person can be expressed as:
local budget per person=(national budget per person) 
x (local age index) x (local additional needs index) x 
(local input price index) x (local DFT index)
where: (1) the age index reflects the demographic 
profile of the local population; (2) the additional needs 
index reflects local deprivation and other factors likely to 
influence the need for public health expenditure; (3) the 
input price index (MFF) reflects prices in the local health 
economy and (4) the distance from target (DFT) index 
reflects how far each LA’s actual budget allocation is from 
its target allocation.16 The DFT index reflects the fact that, 
periodically, the national ministry revises the funding 
formula and this, together with routine data updates, 
generates a new target budget allocation for each LA. For 
some LAs, the new funding rule might generate a large 
change in its target allocation and, to avoid sudden large 
reductions in actual allocations (budgets), such changes 
are phased into actual budgets over a number of years 
in accordance with the Department of Health’s ‘pace of 
change’ policy.18
Two of the four adjustment factors in equation (2)—
the MFF and the DFT—are relevant for all three compo-
nents of the public health resource allocation formula 
for 2013/2014. We use these variables as instruments to 
predict expenditure, and then estimate the relationship 
between this predicted level of expenditure and health 
outcomes. The MFF and DFT are valid instruments if 
they are not related to health outcomes (except through 
their influence on expenditure) or an unobserved 
confounder.16 17
The local input price index (MFF), which will reflect 
characteristics of the local (health) economy, could be 
correlated with unmeasured determinants of mortality 
(ie, an unobserved confounder). However, we have over a 
dozen potential socioeconomic covariates (including the 
Index of Multiple Deprivation) in the baseline mortality 
equation and hence it is difficult to imagine what effect 
the input price index would detect that our covari-
ates do not (see online supplemental appendix A2 for 
further discussion of this instrument). The DFT variable 
will largely reflect: (1) the level of PCT expenditure in 
2010/2011 associated with those public health activities 
that were transferred to LAs in 2013/2014; (2) the public 
health grant funding formula for 2013/2014; and (3) the 
‘pace of change’ policy for the 2013/2014 allocations. 
The latter two factors will be policy choices but it is not 
obvious that the resulting DFT will be endogenous with 
respect to mortality. Moreover, any correlation between 
Figure 1 Causal paths diagram.
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our two instruments and the error term in equation (1) 
is likely to be detected by the Hansen- Sargan test. Hence, 
we use the public health grant MFF and DFT as instru-
ments for public health expenditure when estimating 
equation (1).
Theory provides little guidance as to the identity of 
the appropriate controls in equation (1) so, following 
previous studies, we identify a dozen socioeconomic 
variables—such as the proportion of the working age 
population employed in managerial and professional 
occupations, and the proportion of owner- occupied 
households—as potential controls for the need for public 
health expenditure.17 We start by estimating (1) with all 
socioeconomic variables included as controls. The least 
significant regressor is removed from the specification and 
the equation is re- estimated (backward selection). This 
process—of dropping the least significant regressor and 
re- estimating—continues until there are only significant 
controls remaining (the expenditure term is forced to be 
ever- present). This specification becomes our preferred 
result if it also passes the appropriate statistical tests (eg, 
the instruments are valid and the instruments are strong) 
but, if this is not the case, the specification is adjusted 
(eg, an invalid instrument is removed) and the equation 
re- estimated. When the specification requires no further 
adjustment it becomes our preferred specification.
Initially equation (1) is estimated using the above 
strategy with public health as the sole health expenditure 
variable. We then re- estimate (1)—again using the above 
strategy—but this time including healthcare expenditure 
as an additional endogenous regressor. This variable is 
instrumented in a similar way to public health. Further 
details of this estimation process and the instruments 
for healthcare expenditure are in the online supple-
mental appendix A3. As a sensitivity analysis, we repeat 
our estimation strategy using forward selection to identify 
relevant controls when we have both public health and 
healthcare expenditure in the health outcome equation.
Data
Unitary and upper tier LAs (n=152) are the unit of anal-
ysis in this study but one of them (the Isles of Scilly) is so 
small that the mortality data for this authority is rarely 
disclosed by the Office for National Statistics (ONS) so 
this leaves 151 authorities for analysis. In addition, the 
healthcare expenditure data for one CCG (Wiltshire) for 
2013/2014 is not available so that, when both expendi-
ture variables are included in the estimating equation, 
there are 150 observations for analysis.
With the exception of the CCG healthcare expenditure 
and the instruments for this variable, all of the dataset is 
readily available at the LA level. The healthcare expen-
diture and instrument data have been converted to an 
LA basis using a mapper which uses population levels in 
mid-2012 to allocate (parts of) CCGs to LAs. As LAs vary 
greatly in size, we weight all observations in our analysis by 
their population size. In addition, we use the logarithms 
of all variables in the empirical analysis so that regression 
coefficients can be interpreted as elasticities.
Table 1 reports descriptive statistics for the variables 
employed in this study. Average expenditure per person 
from the public health grant in 2013/2014 was £53 and 
this varied between £18 and £186 per person. Average per 
capita expenditure on healthcare was £1152. The mortality 
measure employed in this study is the (age) standardised 
under 75 years of life lost rate. This mortality rate varies 
considerably across the country, ranging between 267 
(city of London) and 776 (Blackpool) years of life lost 
per 10 000 population.
The DFT instrument for public health expenditure 
averages just over 1.00 but its range suggests that at least 
one LA budget is 46% under its target allocation and 
another LA budget (the City of London) is 562% above 
its target allocation. The MFF instrument for public 
health expenditure reveals that some LAs face unit costs 
between 8% lower and 21% higher than the average. 
The instruments for healthcare expenditure also reveal 
considerable geographical variation with, for example, 
some LAs being 7% below and others being 23% above 
their target allocations.
The dozen potential socioeconomic controls for the 
need for health are also listed in table 1. These census- 
based variables are constructed using the 2011 census. 
They show that, for example, on average, 13% of all resi-
dents are born outside the European Union, 31% of the 
working- age population are employed in managerial and 
professional occupations, and 62% of households are 
owner occupied. Again, these averages mask considerable 
variation across LAs; the proportion of residents born 
outside the EU varies from less than 2% to more than 
50%, and the extent of owner occupation ranges between 
26% and 81% of all households. Further details about the 
data can be found elsewhere.19 All specifications are esti-
mated using the ivreg2 command in Stata (version 15).20
Patient and public involvement
Neither patients nor the public were involved in the 
design, or conduct, or reporting, or dissemination of our 
research.
RESULTS
With the public health grant as the only expenditure variable
Estimation of equation (1) with public health as the sole 
expenditure variable generates the result shown in column 
1 of table 2. Application of the backward selection process 
generates the more parsimonious specification shown in 
column 2 of table 2. In this, public health expenditure 
has a modest but statistically significant negative associa-
tion with mortality, expenditure is endogenous, there is 
no evidence of weak instruments (the Kleibergen- Paap 
F statistic exceeds the rule- of- thumb threshold value 
(=10)), and the specification passes the reset test. Details 
of the intermediate estimations associated with this back-
ward selection process are in the online supplemental 
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appendix A4 (see online supplemental table A1 for the 
second- stage and online supplemental table A2 for the 
first- stage results).
With both the public health grant and healthcare as the 
expenditure variables: backward selection
Estimation of equation (1) with both public health and 
healthcare expenditure as endogenous regressors gener-
ates the result shown in column 3 of table 2. This speci-
fication includes five instruments (two for public health 
expenditure and three for healthcare expenditure). 
Application of the backward selection process gener-
ates the more parsimonious result shown in column 4 
where both expenditure variables have the anticipated 
negative association with mortality, they are endogenous, 
the instrument set is valid, and the instrument sets for 
both endogenous variables are individually strong (the 
Sanderson- Windmeijer F- statistics are around ten or 
better). Details of the intermediate estimations associ-
ated with the backward selection process are in the online 
supplemental appendix A4 (see online supplemental 
table A3 for the second- stage and online supplemental 
table A4 for the first- stage results).
With both the public health grant and healthcare as the 
expenditure variables: forward selection
The use of backward selection to identify relevant covari-
ates when theory provides little guidance does not always 
meet with universal approval, and hence results are also 
reported using forward selection (see table 2, columns 5 
Table 1 Descriptive statistics for study variables
Variable description Observations Mean SD Minimum Maximum
Health expenditure variables
  Public health grant: expenditure per person, £, 
2013/2014
152 52.6 25.2 18.5 186.2
  Healthcare spend per person, £, 2013/2014 151 1152.1 75.8 1019.9 1479.1
Mortality variable
  Standardised years of life lost rate, 2013/2014/2015 151 443.3 85.0 267.5 775.9
Instruments for expenditure
  Distance from target (public health) 152 1.0667 0.5362 0.5392 6.6247
  Market Forces Factor (public health) 152 1.0122 0.0790 0.9151 1.2076
  Distance from target (healthcare: total) 152 1.0055 0.0515 0.9282 1.2250
  Age index (healthcare: prescribing) 152 0.9776 0.1283 0.6422 1.3007
  Market Forces Factor (healthcare: HCHS) 152 1.0063 0.0643 0.9319 1.1416
Socioeconomic controls
  Proportion of all residents born outside the European 
Union
152 0.1281 0.1147 0.0144 0.5060
  Proportion of population in white ethnic group 152 0.8364 0.1626 0.2897 0.9882
  Proportion of population providing unpaid care 152 0.1008 0.0138 0.0651 0.1289
  Proportion of population aged 16–74 with no 
qualiications
152 0.2469 0.0606 0.0720 0.3874
  Proportion of households without a car 152 0.2862 0.1248 0.0899 0.6940
  Proportion of households that are owner occupied 152 0.6190 0.1152 0.2611 0.8086
  Proportion of households that are one pensioner 
households, 2011
152 0.1206 0.0208 0.0596 0.1667
  Proportion of households that are lone parent 
households with dependent children
152 0.0745 0.0185 0.0208 0.1436
  Proportion of population aged 16–74 that are 
permanently sick
152 0.0424 0.0149 0.0086 0.0879
  Proportion of those aged 16–74 that are long- term 
unemployed
152 0.0183 0.0058 0.0043 0.0367
  Proportion of those aged 16–74 in employment that are 
working agriculture
152 0.0064 0.0099 0.0003 0.0572
  Proportion of those aged 16–74 in managerial and 
professional occupations
152 0.3114 0.0769 0.1835 0.6674
  Index of Multiple Deprivation (2010) 152 23.0753 8.6040 5.4466 43.4465  on N
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Table 2 Derivation of preferred speciications for public health expenditure, 2013/2014
Variables
(1)
All causes
2013/2014 PH spend
SYLLR 2013/2014/2015
Outcome model
Instrument PH spend
Weighted
IV second stage
Full speciication
(2)
All causes
2013/2014 PH spend
SYLLR 2013/14/15
Outcome model
Instrument PH spend
Weighted
IV second stage
Derived speciication
(3)
All causes
2013/2014 PH & PB spend
SYLLR 2013/14/15
Outcome model
Instrument PH&PB spend
Weighted
IV second stage
Full speciication
Backward selection
(4)
All causes
2013/2014 PH & PB spend
SYLLR 2013/14/15
Outcome model
Instrument PH&PB spend
Weighted
IV second stage
Derived speciication
Backward selection
(5)
All causes
2013/2014 PH & PB spend
SYLLR 2013/14/15
Outcome model
Instrument PH&PB spend
Weighted
IV second stage
Initial speciication
Forward selection
(6)
All causes
2013/2014 PH & PB spend
SYLLR 2013/14/15
Outcome model
Instrument PH&PB spend
Weighted
IV second stage
Derived speciication
Forward selection
Public health spend per person −0.084** (0.041) −0.115** (0.048) −0.024 (0.037) −0.081** (0.034) −0.006 (0.025) −0.144*** (0.040)
Healthcare spend per person −0.551 (0.413) −0.672*** (0.233) −1.012*** (0.244) −0.837*** (0.269)
IMD 2010
  
0.203*** (0.075) −0.505*** (0.157) 0.253*** (0.062) 0.221*** (0.063)
Proportion of all residents born 
outside the EU
  
−0.016 (0.018) −0.043* (0.024) −0.084*** (0.019) −0.070*** (0.019)
Proportion of population in white 
ethnic group
0.246*** (0.060) 0.226*** (0.051)
Proportion of population providing 
unpaid care
  
−0.439*** (0.167) −0.231** (0.091) −0.399*** (0.144) −0.479*** (0.096) −0.547*** (0.122)
Proportion of population aged 16–74 
with no qualiications
−0.034 (0.112) −0.111 (0.105)
Proportion of households without 
a car
−0.062 (0.072) −0.033 (0.087)
Proportion of households that are 
owner occupied
0.129* (0.071) 0.090 (0.075)
Proportion of households that are 
one pensioner households
−0.082 (0.084) −0.023 (0.079)
Lone parent households with 
dependent children
0.056 (0.060) −0.048 (0.082)
Proportion of population aged 16–74 
that are permanently sick
0.315*** (0.070) 0.475*** (0.068) 0.237*** (0.068) 1.187*** (0.331) 0.554*** (0.031) 0.601*** (0.051)
Proportion of those aged 16–74 that 
are long- term unemployed
0.039 (0.057) 0.085 (0.060) 0.156*** (0.040)
Proportion of those aged 16–74 
working agriculture
−0.015 (0.010) −0.007 (0.013)
Proportion of those aged 16–74 in 
professional occupations
−0.201*** (0.077) −0.205*** (0.049) −0.259*** (0.072) −0.194*** (0.045)
IMD 2010, squared 0.092*** (0.028)
Proportion of population aged 16–74 
permanently sick, squared
0.138*** (0.052)
Constant 5.532*** (0.649) 7.936*** (0.402) 8.714*** (2.852) 11.286*** (1.409) 15.008*** (1.756) 13.666*** (1.762)
Observations 151 151 150 150 150 150
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Variables
(1)
All causes
2013/2014 PH spend
SYLLR 2013/2014/2015
Outcome model
Instrument PH spend
Weighted
IV second stage
Full speciication
(2)
All causes
2013/2014 PH spend
SYLLR 2013/14/15
Outcome model
Instrument PH spend
Weighted
IV second stage
Derived speciication
(3)
All causes
2013/2014 PH & PB spend
SYLLR 2013/14/15
Outcome model
Instrument PH&PB spend
Weighted
IV second stage
Full speciication
Backward selection
(4)
All causes
2013/2014 PH & PB spend
SYLLR 2013/14/15
Outcome model
Instrument PH&PB spend
Weighted
IV second stage
Derived speciication
Backward selection
(5)
All causes
2013/2014 PH & PB spend
SYLLR 2013/14/15
Outcome model
Instrument PH&PB spend
Weighted
IV second stage
Initial speciication
Forward selection
(6)
All causes
2013/2014 PH & PB spend
SYLLR 2013/14/15
Outcome model
Instrument PH&PB spend
Weighted
IV second stage
Derived speciication
Forward selection
Endogeneity test statistic 11.369 10.579 5.928 17.683 6.137 22.853
Endogeneity p value 0.001 0.001 0.052 0.000 0.046 0.000
Hansen- Sargan test statistic 14.750 20.849 1.667 23.78 1.465
Hansen- Sargan p value 0.000 0.000 0.197 0.000 0.226
Kleibergen- Paap LM test statistic 26.821 32.762 9.027 16.034 24.002 18.331
Kleibergen- Paap p value 0.000 0.000 0.060 0.000 0.000 0.000
Kleibergen- Paap F statistic 69.320 120.521 2.323 8.979 7.220 11.627
Pesaran- Taylor reset statistic 10.116 2.456 1.405 0.175 0.073 0.466
Pesaran- Taylor p value 0.001 0.117 0.236 0.676 0.788 0.495
SW_PH F- statistic n/a n/a 70.796 70.796 100.608 57.002
SW_PH p value n/a n/a 0.000 0.000 0.000 0.000
SW_PB F- statistic n/a n/a 13.469 13.469 9.052 17.375
SW_PB p value n/a n/a 0.000 0.000 0.000 0.000
Robust SE in brackets.
*P<0.05, **P<0.01, ***P<0.001.
EU, European Union; IMD, Index of Multiple Deprivation; n/a, not applicable; SW_PB, Sanderson- Windmeijer test statistic for programme budgeting healthcare expenditure; SW_PH, Sanderson- Windmeijer test statistic for public health expenditure; 
SYLLR, standardised under 75 years of life lost rate.
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and 6). Column 5 shows the result with the inclusion of 
the most significant single control (‘permanently sick’) 
with the same five instruments from the ‘full’ specification 
in column 3. Further re- estimation, with the inclusion of 
additional significant controls, generates the result shown 
in column 6. No further additional significant controls 
could be found and, as the result in column 6 is both 
in line with both our theoretical priors and passes the 
appropriate statistical tests, this is our preferred specifica-
tion using forward selection. Details of the intermediate 
estimations associated with the forward selection process 
are in the online supplemental appendix 1 (see online 
supplemental tables A5 and A6 in online supplemental 
appendix A4.
The estimation of a mortality equation that includes both 
public health and healthcare expenditure generates an 
outcome elasticity for public health expenditure of −0.081 
using backward selection and an elasticity of −0.144 using 
forward selection. The midpoint of these two elasticities 
is almost identical to the elasticity estimated without the 
inclusion of healthcare expenditure (=−0.115). Although 
statistically significant, these elasticities appear relatively 
modest when compared with the elasticity associated with 
healthcare expenditure (which, in this paper, is several 
times larger than the public health elasticity). However, 
this comparison is misleading because it fails to allow for 
the relative size of the two budgets (£65 billion for health-
care and £2.5 billion for public health in 2013/2014). The 
coefficient on public health expenditure from column 2 
of table 2 implies that a 1% increase in such expenditure 
(=£25.107 m) in 2013/2014 is associated with a 0.115% 
decline in mortality. With 446 560 deaths in England in 
2013, the coefficient on public health expenditure implies 
that an additional £25.107 m of expenditure would avert 
514 deaths (=0.115% of 446 560) and that the cost per 
death averted would be £48 894. Similar calculations can 
be made for the other outcome elasticities reported in 
table 2 and summarised in columns 1 and 2 of table 3. 
The resulting cost per death averted estimates are shown 
in columns 3 and 4 of table 3. The estimates reveal that 
the healthcare cost of a death averted is between three 
times (backward selection) and four times (forward selec-
tion) the size of the public health cost.
Although interesting, the cost per death averted esti-
mates are of limited relevance because a large proportion 
of CCG expenditure is not directed towards saving life 
but to improving the quality of life. To capture the full 
health effects associated with a change in expenditure, 
we require a measure that incorporates both survival and 
quality of life effects, that is, we require a measure of the 
number of quality- adjusted life- years (QALYs).
Unfortunately, direct estimates of the QALY effects of 
public health expenditure are not available. However, 
previous work has used the estimated mortality effects of 
changes in NHS healthcare expenditure to calculate the 
QALY effects.12 We can apply the same approach to esti-
mate the QALY effects of public health expenditure if we 
assume that the distribution of mortality benefits across 
disease areas for public health expenditure is similar to 
that for CCG expenditure.
Previous work estimated that, in 2012/2013, a 1% 
change in total healthcare expenditure generates 65 773 
QALYs across all disease areas and this result implies an 
all- cause mortality elasticity of −1.028. This suggests that 
a 1% reduction in all- cause mortality is associated with 
a gain of 63 981 QALYs (65 773/1.028).12 Therefore, a 
1% increase in public health expenditure (£25.107 m), 
which reduces all- cause mortality by 0.115% is associated 
with a gain of 7358 QALYs (0.115×63 981). This 7358 
QALY gain, together with the additional expenditure of 
£25.107 m, implies a cost per QALY for local public health 
expenditure of £3412 (column 5, table 3).
Similar calculations can be made for the two other 
public health elasticities (−0.081 and −0.144) reported 
Table 3 Mortality elasticities and cost per quality- adjusted life year (QALY) estimates for public health and healthcare 
expenditure, 2013/2014
Outcome 
speciication
Mortality 
elasticity 
associated with 
public health 
expenditure
Mortality 
elasticity 
associated 
with healthcare 
expenditure
Cost per death 
averted (£) Cost per QALY (£)
Health (QALY) gains 
associated with £1bn 
budget boost
Public 
health Healthcare
Public 
health Healthcare
Public 
health Healthcare
col 1 col 2 col 3 col 4 col 5 col 6 col 7 col 8
With public health spend only
Backward 
selection
−0.115 (0.048) n/a £48 894 n/a £3412 n/a 293 083 n/a
With public health and healthcare spend
(A) Backward 
selection
−0.081 (0.034) −0.672 (0.233) £69 414 £213 780 £4845 £14 912 206 398 67 060
(B) Forward 
selection
−0.144 (0.040) −0.837 (0.269) £39 047 £171 631 £2725 £11 973 366 973 83 521
n/a, not applicable.
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in table 2 and the implied cost per QALY estimates are 
£4845 and £2725, respectively (see column 5 of table 3). 
Using the same method, we can also use convert the all- 
cause healthcare elasticities in column 2 of table 2 into 
cost per QALY estimates. The backward selection elas-
ticity (=−0.672) implies a cost per QALY of £14 912, while 
the forward selection elasticity (=−0.837) implies a cost 
per QALY of £11 973 (see column 6 of table 3).
Another way to look at the impact of changes in expen-
diture is to calculate the total health gains/losses asso-
ciated with any such change. For example, two leading 
health charities recently estimated that (local) public 
health funding would have to increase by £1 billion in 
2020/2021 for real expenditure per person to be restored 
to its 2015/2016 level.21 We can use our cost per QALY 
estimates to calculate the total health gains associated 
with such a budget boost. If the £1 billion is allocated to 
public health then the total health gain will be 206 398 
QALYs (=£1bn/£4845). This calculation uses the most 
conservative of the two elasticities for health outcomes 
(−0.081) associated with public health expenditure. Alter-
natively, if the additional £1 1 billion is allocated to health-
care then the total health gain will be 67 060 QALYs (=£1 
billion/£14 912). This calculation uses the most conser-
vative of the two elasticities for health outcomes (−0.672) 
associated with healthcare expenditure.
Similar health gain calculations can be made using the 
(less conservative) elasticities obtained using the forward 
selection process. The health gain estimates for public 
health and NHS treatment expenditure, and for forward 
and backward selection, are shown in columns 7 and 8 of 
table 3. These health gain estimates, together with 95% 
CIs, are illustrated graphically in figure 2.
Using the point and SE estimates associated with the 
mortality elasticities in table 3, we undertook a simulation 
study of the difference between the public health and CCG 
QALY gains associated with the budget boost described in 
columns 7 and 8 of table 3. We made one million pairs 
of draws from the two distributions. We found that the 
public health QALY gain was greater than the CCG QALY 
gain in just over 94% of the draws from the backward 
selection estimates, and that this proportion increased 
to over 99% when the forward selection estimates were 
used. We conclude that the marginal public health QALY 
effect is greater than the CCG healthcare effect.
DISCUSSION
If we compare the average of the backward and forward 
selection estimates, then public health expenditure 
appears to be about three to four times more productive 
than healthcare expenditure; that is, the prevention cost 
per QALY is about £3800 whereas the treatment cost is 
£13 500. Similarly, the total health gains associated with 
a spending boost in public health are about three and 
a half times as great as those associated with the same 
boost in healthcare expenditure. This finding—that 
public health offers a much better return than health-
care at the margin—is also reported by other (American) 
studies.10 22 Our (marginal) cost per QALY estimate for 
the public health grant (£3800) is about halfway between 
the median cost per QALY associated with public health 
interventions assessed by NICE between 2005 and 2010 
(£1053), and between 2011 and 2016 (£7843).8
Our cost per QALY estimates for the public health grant 
can also be compared with the return on investment (ROI) 
associated with the public health interventions revealed by 
a systematic search of the literature.23 This reported that, 
across both local and national interventions, a median 
ROI of 14.3–1. Putting aside average versus marginal 
Figure 2 Total health gains associated with a £1 billion budget boost for public health and NHS treatment expenditure, by 
method of selection of covariates. NHS, National Health Service; QALYs, quality- adjusted life years.
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differences, we can convert the cost per QALY associated 
with the public health grant (of about £3800) into a soci-
etal ROI of about 15–1 if we assume that the value of a 
QALY is about £60 000 (this is the figure used by Treasury 
to evaluate public sector programmes).24 Thus our cost 
per QALY estimates are very much in line with the find-
ings from other studies that have used very different data 
sets and very different approaches to estimation.
Our findings suggest that at the margin public health 
expenditure is very productive of health and more produc-
tive than NHS expenditure. This suggests that the reallo-
cation of resources from NHS healthcare to public health 
is likely to improve health outcomes overall and that the 
squeeze on the public health grant while protecting NHS 
expenditure over recent years is likely to have reduced 
health outcomes. It also means that new investments in 
public health interventions need to cost less than £3800 
per QALY to be accommodated within current levels of 
funding.
Our results also suggest that NHS expenditure is very 
productive of health (about £13 500 per QALY) and that 
it is considerably more productive than: (1) the norm 
(£30 000 per QALY) used by NICE to judge whether new 
technologies are cost- effective and (2) HM Treasury’s 
value of a QALY (£60 000) when assessing public sector 
projects.24 Our results also suggest that the inclusion of 
prevention expenditure in the health outcome equation 
does not materially affect the estimated cost per QALY 
associated with treatment expenditure. The cost per 
QALY for NHS expenditure reported here is similar to 
previous estimates where public health expenditure was 
excluded.11 12 17
Different levels of expenditure on local public health 
services may affect mortality both directly and indirectly. 
For example, a recent review estimated that approxi-
mately one in five hospital in- patients in the UK are using 
alcohol harmfully, and one in ten is alcohol- dependent.25 
These figures are ten and eight times higher, respec-
tively, than the general population.25 Reductions in local 
community- based alcohol misuse services might increase 
alcohol- related mortality rates. They might also increase 
non- alcohol- related mortality as addicts, who would have 
been treated in the community, now require hospitalisa-
tion and, by occupying a bed, delay other patients’ access 
to hospital services.
Although our results are plausible, this study is not 
without its limitations. First, our focus is on the impact 
of the public health grant (£2.5bn in 2013/2014) and we 
ignore the impact of other health- related expenditure 
(eg, such as social care). Second, we ignore the impact 
of national public health programmes (eg, for national 
immunisation and national screening programmes). 
These are the responsibility of the NHS Commissioning 
Board and are omitted because we do not have data for 
expenditure on national programmes by local area. Also, 
there will be some treatment expenditure within the 
public health grant, and there will be some prevention 
spend within the measure of CCG healthcare expenditure.
Moreover, equation (1) is static in the sense that it 
assumes that all health benefits occur contemporaneously 
with expenditure. However, our empirical implemen-
tation of (1) does slightly better than this because our 
outcome measure reflects not only mortality in the same 
year as expenditure but also in the two subsequent years. 
In a recent Californian study just over half of the cumula-
tive lives saved as a result of a single year of public health 
spending occurred in the 2 years immediately following 
that expenditure.26 Nevertheless we readily acknowledge 
that, for some public health expenditure, the health 
benefits might arise many years after the expenditure has 
occurred. This is particularly likely to be the case where 
expenditure is directed at encouraging healthy lifestyles, 
where some benefits may occur two or three decades after 
the actual expenditure.
However, this study is constrained by the available 
public health expenditure data which are almost exclu-
sively cross- sectional (a funding formula for public health 
was first introduced in 2013/2014). Implicitly we are 
assuming that the data represent a quasi long- run equilib-
rium situation, that relative expenditure levels and health 
outcomes within each LA have been reasonably stable over 
a period of time, and that any lagged of effect of current 
expenditure on future mortality is offset by the impact 
of previous expenditure on current mortality. These are 
not unreasonable assumptions in the English context but 
they are just assumptions, and they might be less appro-
priate for other geographies where, for example, relative 
outcomes have changed through time.
The final limitation that must be mentioned is that 
there is always the possibility that we have omitted a rele-
vant variable (eg, one that affects both mortality and 
expenditure) from our regression specifications and such 
an omission might affect our results.
CONCLUSIONS
An increase in public health expenditure is more 
productive of health than a change in NHS healthcare 
expenditure, and hence the recent proposal to shift 
resources away from the latter and towards the former 
is an evidence- based one. However, NHS healthcare 
expenditure is also productive of health and the cost per 
QALY (£13 500) is less than one- quarter of the value of a 
QALY (£60 000) used by Treasury when evaluating public 
sector projects. These comparisons suggest that addi-
tional prevention and healthcare expenditure, whether 
funded through additional taxation, borrowing or real-
location from other spending departments, appear good 
value when compared with the Treasury’s estimates of the 
consumption value of health. Our cost per QALY calcula-
tions reveal that public health expenditure appears to be 
about three to four times more productive at the margin 
than healthcare expenditure. Thus Benjamin Franklin’s 
axiom—that ‘an ounce of prevention is worth a pound of 
cure’—is correct in this context in the sense that preven-
tion is more productive than cure but, with 16 ounces to 
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the pound, the adage rather exaggerates the size of this 
advantage.
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